ING Groep NV reduced its stake in Hologic, Inc. (NASDAQ:HOLX) by 83.4% during the third quarter, according to its most recent filing with the SEC. The fund owned 10,059 shares of the medical equipment provider’s stock after selling 50,691 shares during the quarter. ING Groep NV’s holdings in Hologic were worth $369,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Hall Laurie J Trustee raised its stake in Hologic by 10.2% in the 2nd quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock valued at $110,000 after acquiring an additional 225 shares during the period. Commonwealth Bank of Australia raised its stake in Hologic by 31.0% in the 2nd quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock valued at $114,000 after acquiring an additional 600 shares during the period. MPS Loria Financial Planners LLC bought a new stake in Hologic in the 2nd quarter valued at about $191,000. National Asset Management Inc. bought a new stake in Hologic in the 2nd quarter valued at about $203,000. Finally, Cambridge Investment Research Advisors Inc. bought a new stake in Hologic in the 2nd quarter valued at about $213,000. 93.80% of the stock is currently owned by institutional investors.

Shares of Hologic, Inc. (NASDAQ HOLX) opened at $41.72 on Friday. Hologic, Inc. has a 52-week low of $35.76 and a 52-week high of $46.80. The firm has a market capitalization of $11,151.40, a PE ratio of 20.02, a PEG ratio of 1.96 and a beta of 0.93. The company has a current ratio of 0.79, a quick ratio of 0.61 and a debt-to-equity ratio of 0.79.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The firm had revenue of $802.90 million for the quarter, compared to analysts’ expectations of $792.54 million. During the same period in the prior year, the business posted $0.52 earnings per share. The company’s revenue was up 10.5% on a year-over-year basis. sell-side analysts predict that Hologic, Inc. will post 2.12 EPS for the current year.

A number of equities research analysts recently issued reports on the company. Deutsche Bank lowered their price objective on Hologic from $51.00 to $49.00 and set a “buy” rating on the stock in a research note on Thursday, August 3rd. Goldman Sachs Group cut Hologic from a “conviction-buy” rating to a “buy” rating and lowered their price objective for the company from $48.00 to $47.00 in a research note on Thursday, August 3rd. Royal Bank Of Canada lowered their price objective on Hologic from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research note on Thursday, August 3rd. Zacks Investment Research upgraded Hologic from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. Finally, Barclays lowered their price objective on Hologic from $53.00 to $51.00 and set an “overweight” rating on the stock in a research note on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $47.54.

In related news, Director Elaine Ullian sold 9,282 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $40.50, for a total value of $375,921.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Karleen Marie Oberton sold 1,023 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $39.84, for a total transaction of $40,756.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 35,972 shares of company stock worth $1,385,977. Company insiders own 0.79% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Hologic, Inc. (HOLX) Shares Sold by ING Groep NV” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/12/01/hologic-inc-holx-shares-sold-by-ing-groep-nv.html.

Hologic Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.